Prime Medicine Q1 net loss $45.8M; FDA clears IND for CGD Prime Editing therapy

Prime Medicine, Inc.

2024-Q1 EPS reported -$0.44 revenue$591,000

Net loss $45.8M (vs $39.4M Q1 2023); cash $224.2M as of March 31, 2024.
FDA cleared IND for PM359 for chronic granulomatous disease—first Prime Editing product to enter clinic.
Phase 1/2 trial planned; initial clinical data expected in 2025.
Appointed Tony Coles, M.D. as senior advisor; brings biopharma leadership.
Presented preclinical data at ASGCT supporting specificity and delivery of Prime Editing platform.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Prime Medicine, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

today reported financial results for the first quarter ended March 31, 2024

View on SEC.gov

1048 earnings releases filed in the last 30 days. Browse all earnings releases →

Prime Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-022466

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.